Skip to main content

Grafa News and Videos — Page 1559

Latest

Grafa

NervGen Pharma secures FDA alignment for Phase 3 registrational trial in spinal cord injury

NervGen Pharma (NASDAQ:NGEN), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system repair, has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), gaining alignment on the design of its Phase 3 registrational study, RESTORE.

Read more: NervGen Pharma secures FDA alignment for Phase 3 registrational trial in spinal cord injury
Grafa

Precigen projects record Q1 revenue following permanent J-Code for PAPZIMEOS

Precigen (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of gene and cell therapies, has announced a significant acceleration in the commercial rollout of PAPZIMEOS™ (zopapogene imadenovec-drba), projecting first-quarter 2026 revenue to exceed $18 million.

Read more: Precigen projects record Q1 revenue following permanent J-Code for PAPZIMEOS
Grafa

Soleno Therapeutics withdraws European marketing application for VYKAT XR

Soleno Therapeutics (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel treatments for rare diseases, announced on April 7, 2026, that it has voluntarily withdrawn its Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) for VIOKAT prolonged-release tablets.

Read more: Soleno Therapeutics withdraws European marketing application for VYKAT XR
Grafa

MarketAxess posts record credit trading volumes for March and first quarter 2026

MarketAxess Holdings (NASDAQ:MKTX), the operator of a leading electronic trading platform for fixed-income securities, reported record total credit average daily volume (ADV) for both March 2026 and the first quarter ended March 31, 2026, driven by a surge in portfolio and block trading activity.

Read more: MarketAxess posts record credit trading volumes for March and first quarter 2026
Grafa

Nuvalent submits new drug application to FDA for ALK-positive lung cancer therapy

Nuvalent (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, announced on April 7, 2026, the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for neladalkib.

Read more: Nuvalent submits new drug application to FDA for ALK-positive lung cancer therapy

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift